Oppenheimer analyst Michael Wiederhorn maintained a Buy rating on Centene (NYSE:CNC) on Tuesday, setting a price target of $90, which is approximately 43.31% above the present share price of $62.8.
Wiederhorn expects Centene to post earnings per share (EPS) of -$0.02 for the first quarter of 2021.
The current consensus among 13 TipRanks analysts is for a Moderate Buy rating of shares in Centene, with an average price target of $76.54.
The analysts price targets range from a high of $94 to a low of $65.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $28.29 billion and a net profit of $15 million. The company's market cap is $36.52 billion.
According to TipRanks.com, Oppenheimer analyst Michael Wiederhorn is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 23.3% and a 75.13% success rate.
Centene Corp. engages in the provision of programs and services to government sponsored healthcare programs. It operates through the following segments: Managed Care and Specialty Services. The Medicaid Managed Care segment provides health plan coverage to individuals through government subsidized programs through Medicaid. The Specialty Services segment offers healthcare services and products to state programs, correctional facilities, healthcare organizations, employer groups, and other commercial organizations. The company was founded in 1984 and is headquartered in St. Louis, MO.